GPT and metabolic dysfunction-associated steatotic liver disease: The subgroup analysis presented that DASH diet consumption could significantly reduce ALT in patients below 44 years old (WMD: −6.542 IU/L, 95% CI: −9.957, −3.127, p < 0.001), baseline serum ALT over 30 IU/L (WMD: −7.182 IU/L, 95% CI: −9.79, −4.575, p < 0.001), BMI below 30 kg/m2 (WMD: −7.237 IU/L, 95% CI: −11.207, −3.266, p < 0.001), and patients with NAFLD (WMD: −6.542 IU/L, 95% CI: −9.957, −3.127, p < 0.001).